Skip to main content

Table 2 Treatment course and prognosis of all patients

From: Surgical spacer placement for proton radiotherapy in locally advanced pancreatic body and tail cancers: initial clinical results

Age, Sex Tumor size (mm) Reason for UR-LA Pre-treatment
Regimen (course)
CA19-9 before surgery
(U/ml)
Protocol
GyE / Fr
Post-treatment regimen Progression free survival
(months)
Progression pattern Status, survival time (months) after diagnosis / spacer surgery
67, M 50 CA, SMA None 3267 Proton, 67.5 / 25 Gemcitabine 3 Peritoneal dissemination Dead, 12 / 10
48, F 60 CA Gemcitabine (2) 598 Proton, 67.5 / 25 Gemcitabine 9 Peritoneal dissemination Dead, 16 /11
68, F 30 CA S-1 (2) 35 Proton, 70.2 / 26 S-1 5 Peritoneal dissemination Dead, 11 / 8
65, M 45 CA None 1066 Proton, 67.5 / 25 Gemcitabine NA - Dead, 10 / 9
55, M 34 CA None 7 Proton, 70.2 / 26 Gemcitabine 18 Liver metastasis/Peritoneal Dissemination Dead, 22 / 21
44, F 25 CA S-1 (1) 102 Proton, 70.2 / 26 Gemcitabine 38 Local progression Dead, 50 / 47
68, F 31 CA Gemcitabine (1) 1 Proton, 67.5 / 25 Gemcitabine 16 Liver metastasis / Local progression Dead, 31 / 30
68, F 21 CA Gemcitabine (1) 127 Proton, 67.5 / 25 Gemcitabine 31 Lung metastasis Dead, 52 / 50
65, F 46 CA, SMA Gemcitabine plus nab-paclitaxel (6) 860 Proton, 67.5 / 25 Gemcitabine NA - Alive, 14 / 7
  1. CA celiac artery, SMA superior mesenteric artery, S-1 Tegafur, Gimeracil, Oteracil Potassium, NA not available